Life Sciences Weekly - Episode 9

Recorded: August 2, 2025

Join us for Episode 9 of Life Sciences Weekly as we break down a week of volatility and progress across biotech, pharma, and medtech. With all major sector ETFs sliding—XBI down 2%, XPH off nearly 4%, and XHE dipping close to 4%—we spotlight sharp stock swings from Sarepta’s big rebound to Novo Nordisk’s record plunge.

This episode covers the latest FDA clearances, from rapid COVID-19 diagnostics and wearable heart monitors to innovative radiotherapy platforms and single-use gastroscopes. On the drug front, we highlight new approvals for rare diseases, vision impairment, and generic antidepressants, plus expanded uses for leading therapies and safety label updates for top vaccines and biologics.

We also report on rigorous FDA enforcement actions, major funding rounds in AI and radiopharma, and high-impact M&A—including Sanofi’s China deal for an RNAi rare disorder drug and Monogram Technologies’ historic autonomous robotic knee surgery, setting the stage for the future of orthopedic care.

Don’t miss this week’s industry spotlight on medtech innovation, where AI, robotics, and advanced imaging are converging to revolutionize precision surgery and patient outcomes. Tune in for expert analysis, market movers, regulatory milestones, and the trends shaping the future of life sciences. Stay curious and be well!

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 8

Recorded: July 26, 2025

Tune in to Episode 8 of Life Sciences Weekly with host Matt Davison for a fast-paced recap of the week’s most important developments across biotech, pharma, and medtech. In this episode (July 26, 2025), Matt breaks down ETF sector performance, highlights standout market movers, and examines the biggest regulatory headlines—including major FDA approvals, special drug designations, and enforcement actions like warning letters and product recalls. Catch up on the latest funding news and capital market trends, plus a rapid-fire summary of the week’s major mergers, acquisitions, and strategic partnerships—featuring deals from Eli Lilly, Simtra BioPharma, Sanofi, and more. Finally, the industry spotlight digs into what the appointment of respected biotech veteran Dr. George Tidmarsh as the FDA’s new top drug regulator could mean for drug development and healthcare innovation in the U.S. Stay informed with concise analysis and smart commentary—ideal for professionals, investors, and anyone following cutting-edge science and industry trends.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 7

Recorded: June 28, 2025

In Episode 7 of Life Sciences Weekly, host Matt Davison delivers a comprehensive roundup of the week’s biggest developments in biotech, pharma, and medtech as of June 28, 2025. Tune in for a detailed market snapshot—including ETF performance and sector drivers—before diving into a packed slate of FDA approvals and regulatory actions, from Stryker’s new ankle system and the first sutureless nerve repair device to expanded Alzheimer’s imaging labels and major cancer therapy advances. The episode covers key funding rounds, including CalmWave, ForSight Robotics, and a $2B commitment to Revolution Medicines, alongside major M&A moves like Synthego’s sale, Illumina’s SomaLogic deal, and Gentell’s acquisition of Casex. In the Industry Spotlight, Matt breaks down the FDA’s removal of REMS requirements for most CAR-T cell therapies, a move set to double patient access nationwide. Whether you’re an industry insider or just curious about the future of healthcare, this episode has you covered with in-depth analysis.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 6

Recorded: June 7, 2025

In this episode of Life Sciences Weekly, host Matt Davison recaps a week of strong gains for biotech and pharma, with the S&P Biotech ETF climbing nearly 5% despite ongoing economic and policy headwinds. Medtech companies are adapting to tariff pressures and shifting guidance, while investors watch for renewed M&A activity and regulatory milestones. The episode highlights a wave of FDA approvals, including new cancer therapies, AI-powered diagnostics, and the first whole-room UV-C microbial reduction system. It also covers significant FDA enforcement actions, from warning letters to manufacturers across the globe to high-profile recalls affecting nasal swabs, infusion pumps, and tracheostomy tubes.

Despite a sharp drop in biotech funding last month, we review innovative startups that secured major investments this week, and the M&A landscape is heating up with billion-dollar deals and strategic partnerships. In the Industry Spotlight, Matt examines Elsa, the FDA’s new generative AI tool designed to streamline regulatory review. While Elsa promises to speed up complex tasks and help offset staff reductions, its rapid rollout has sparked debate over accuracy, data security, and readiness for regulatory decision-making. Tune in for a concise, expert breakdown of the latest trends, deals, and innovations shaping the future of life sciences.

**Please Note** We will be taking a 2 week break and resuming with episode 7 on June 28, 2025.  Until then, keep pushing the boundaries of science and stay inspired!  Thank you for listening. 

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly - Episode 5

Recorded: May 31, 2025

In this week’s episode of Life Sciences Weekly (May 31, 2025), we break down the latest market gains, a wave of FDA approvals, and the regulatory trends shaping biotech, medtech, and pharma. We cover major device and drug clearances, highlight new funding rounds and strategic partnerships—including deals from Neuralink, GRIN Therapeutics, and Sun Pharma—and examine the FDA’s latest enforcement actions and recalls.

Our industry spotlight dives into China’s rapid ascent as the global leader in drug development, what it means for U.S. innovation, and how the FDA is responding with stricter oversight and new policy shifts. Tune in for insights on the future of global competition, regulatory change, and the investments driving next-generation therapies.

Stay informed on the top headlines, industry trends, and what’s next in life sciences—all in under an hour.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly – Episode 4

Recorded: May 24, 2025

In this episode, we break down the latest headlines shaping the life sciences industry. Tune in for a recap of key FDA approvals, including innovative medical devices and breakthrough drug therapies, as well as the week’s most significant mergers, acquisitions, and funding rounds. We spotlight the FDA’s new, stricter COVID-19 vaccine approval standards—exploring both the support and controversy they’ve generated—and discuss the FTC’s renewed crackdown on improper patent listings that could pave the way for more affordable generics. Plus, hear about major enforcement actions, the evolving regulatory landscape, and what these changes mean for the future of biotech, pharma, and medtech. Whether you’re an industry insider or just curious about the science shaping tomorrow’s healthcare, this episode delivers the insights you need to stay informed.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly Podcast - Episode 3                                                                  Recorded: May 17, 2025

In Episode 3 of Life Sciences Weekly, host Matt Davison unpacks a pivotal week for the industry, marked by policy shifts, regulatory actions, and a surge in funding. The show opens with a market recap, highlighting renewed financial strength in the U.S. life sciences sector as venture capital, IPOs, and M&A activity rebound.

Matt delivers a comprehensive overview of recent FDA approvals and regulatory updates, from new device clearances and gene therapy advances to first-in-class drug approvals for cancer and rare diseases. The episode then explores FDA enforcement actions, detailing new warning letters and import alerts for both U.S. and international manufacturers over serious GMP and sterility violations.

The startup and funding segment shines a spotlight on major capital raises for companies developing cutting-edge therapies, AI-driven platforms, and next-generation manufacturing, with venture investment fueling demand for specialized lab and biomanufacturing space.

In the Industry Spotlight, Matt breaks down President Trump’s revived “Most Favored Nation” drug pricing policy, examining how the executive order could reshape Medicare drug costs, spark legal battles, and trigger market volatility. The episode wraps with a reminder that regulatory vigilance, innovation, and investment are driving forces as the life sciences landscape continues to evolve.

Stay tuned for more news, analysis, and expert insights next week on Life Sciences Weekly.

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly Podcast – Episode 2
Recorded: May 10, 2025

This week on Life Sciences Weekly, host Matt Davison breaks down a whirlwind of developments shaping the biotech, pharma, and medtech landscape. Tune in for a market recap as volatility rocks the sector, with biotech stocks tumbling after Dr. Vinay Prasad is named the new head of the FDA’s Center for Biologics Evaluation and Research (CBER). Discover why Prasad’s evidence-driven, no-nonsense approach to drug approvals is sending shockwaves through the industry-and what it could mean for gene therapy and vaccine developers.

Get the latest on FDA approvals, including new clearances for AI-powered imaging, at-home cancer screening, and rare disease treatments. Matt covers the FDA’s evolving regulatory pathways, missed approval deadlines amid HHS restructuring, and a notable slowdown in enforcement actions.

In funding news, hear about major venture rounds, strategic investments, and academic-industry partnerships fueling the next wave of innovation-even as IPO windows remain tight. Plus, get a snapshot of Q1’s M&A and licensing trends across medtech and biopharma.

The episode’s Industry Spotlight examines the intersection of regulatory change and unprecedented U.S. investment, with Gilead, AstraZeneca, Novartis, AbbVie, and others pouring billions into domestic R&D and manufacturing. As the FDA tightens its standards and the political climate shifts, find out how life sciences leaders are doubling down on American infrastructure and innovation.

Don’t miss this comprehensive roundup of the week’s top stories, market moves, and the forces shaping the future of life sciences. Subscribe now for your essential industry briefing!

With your Life Sciences Industry Guide, Matt Davison

Life Sciences Weekly delivers a fast-paced, insightful roundup of the latest trends, deals, and regulatory news shaping the global life sciences and medical device industries. In this inaugural episode, recorded May 3, 2025, we break down the week’s market movers, highlighting gains in biotech and medtech stocks and renewed investor confidence.

Dive deep into the latest regulatory updates, including FDA approvals for breakthrough drugs, devices, and gene therapies, as well as significant changes under new FDA Commissioner Dr. Martin Makary-who’s championing modernization, AI integration, and a shift away from animal testing. We spotlight key 510(k), NDA, IND, and BLA approvals, and discuss the FDA’s recent enforcement actions against several drug manufacturers.

Stay ahead of the curve with our comprehensive funding and startup segment, featuring major Series A, B, and C rounds from innovators in digital health, diagnostics, neurostimulation, cell therapy and more. We also cover the latest in mergers and acquisitions, as industry giants and nimble startups alike reshape the sector through strategic deals.

Whether you’re an investor, entrepreneur, clinician, or industry insider, Life Sciences Weekly is your go-to source for the essential news and analysis driving healthcare innovation in 2025.

With your Life Sciences Industry Guide, Matt Davison